DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - NYSE:DOCS - US26622P1075 - Common Stock
62.58 USD
-1.41 (-2.2%)
58.15 USD
-4.43 (-7.08%)
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
DOCS had a positive operating cash flow in the past year.
In the past 5 years DOCS has always been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS has a better Return On Assets (19.52%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 22.93%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has a Return On Invested Capital of 18.77%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.84%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(18.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROIC | 18.77% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
Looking at the Profit Margin, with a value of 39.88%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
Looking at the Operating Margin, with a value of 40.46%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Operating Margin has improved in the last couple of years.
DOCS has a better Gross Margin (90.14%) than 97.14% of its industry peers.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DOCS is creating value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DOCS has an Altman-Z score of 41.47. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 41.47, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 41.47 |
ROIC/WACC1.88
WACC9.96%
2.3 Liquidity
A Current Ratio of 6.47 indicates that DOCS has no problem at all paying its short term obligations.
DOCS's Current ratio of 6.47 is amongst the best of the industry. DOCS outperforms 94.29% of its industry peers.
DOCS has a Quick Ratio of 6.47. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS's Quick ratio of 6.47 is amongst the best of the industry. DOCS outperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.43% over the past year.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.98%.
The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)19.98%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.17%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.47% yearly.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.87% yearly.
EPS Next Y9.97%
EPS Next 2Y10.23%
EPS Next 3Y11.25%
EPS Next 5Y13.47%
Revenue Next Year12.23%
Revenue Next 2Y11.74%
Revenue Next 3Y11.52%
Revenue Next 5Y11.87%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DOCS is valuated quite expensively with a Price/Earnings ratio of 38.16.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
DOCS's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.67.
The Price/Forward Earnings ratio is 36.53, which means the current valuation is very expensive for DOCS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 62.86% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of DOCS to the average of the S&P500 Index (31.86), we can say DOCS is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.16 | ||
| Fwd PE | 36.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than the industry average as 62.86% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.79 | ||
| EV/EBITDA | 40.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)3.83
PEG (5Y)0.48
EPS Next 2Y10.23%
EPS Next 3Y11.25%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
62.58
-1.41 (-2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners90.54%
Inst Owner Change1.04%
Ins Owners1.94%
Ins Owner Change-0.09%
Market Cap11.72B
Revenue(TTM)570.40M
Net Income(TTM)235.13M
Analysts76.92
Price Target72.99 (16.63%)
Short Float %3.45%
Short Ratio3.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.11%
Min EPS beat(2)17.55%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)25.17%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.03%
EPS beat(12)12
Avg EPS beat(12)21.73%
EPS beat(16)16
Avg EPS beat(16)33.54%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)1.38%
Max Revenue beat(2)2.52%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.34%
Revenue beat(12)9
Avg Revenue beat(12)2.13%
Revenue beat(16)12
Avg Revenue beat(16)2.76%
PT rev (1m)3.54%
PT rev (3m)13.08%
EPS NQ rev (1m)0.68%
EPS NQ rev (3m)11.59%
EPS NY rev (1m)0.16%
EPS NY rev (3m)7.01%
Revenue NQ rev (1m)0.46%
Revenue NQ rev (3m)4.93%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.16 | ||
| Fwd PE | 36.53 | ||
| P/S | 19.88 | ||
| P/FCF | 40.79 | ||
| P/OCF | 39.85 | ||
| P/B | 11.43 | ||
| P/tB | 12.53 | ||
| EV/EBITDA | 40.79 |
EPS(TTM)1.64
EY2.62%
EPS(NY)1.71
Fwd EY2.74%
FCF(TTM)1.53
FCFY2.45%
OCF(TTM)1.57
OCFY2.51%
SpS3.15
BVpS5.48
TBVpS5
PEG (NY)3.83
PEG (5Y)0.48
Graham Number14.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROCE | 22.84% | ||
| ROIC | 18.77% | ||
| ROICexc | 96.31% | ||
| ROICexgc | 172.66% | ||
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% | ||
| FCFM | 48.73% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 62.32% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.9% | ||
| Profit Quality | 122.2% | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 | ||
| Altman-Z | 41.47 |
F-Score8
WACC9.96%
ROIC/WACC1.88
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y9.97%
EPS Next 2Y10.23%
EPS Next 3Y11.25%
EPS Next 5Y13.47%
Revenue 1Y (TTM)19.98%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.17%
Revenue Next Year12.23%
Revenue Next 2Y11.74%
Revenue Next 3Y11.52%
Revenue Next 5Y11.87%
EBIT growth 1Y26.79%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year15.19%
EBIT Next 3Y13.45%
EBIT Next 5Y12.98%
FCF growth 1Y54.23%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y53.19%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
Can you provide the valuation status for DOXIMITY INC-CLASS A?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 9.97% in the next year.